Logo
x

Search

Subscribe Now

Boehringer Ingelheim

The US FDA Accepts NDA of Boehringer Ingelheim’s Zongertinib for HER2 (ERBB2)-Mutant NSCLC

The US FDA Accepts NDA of Boehringer Ingelheim’s Zongertinib for HER2 (ERBB2)-Mutant NSCLC

  • February 20, 2025
Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension

Boehringer Ingelheim Launches Semintra in the EU to Treat Feline Hypertension

  • February 13, 2025
Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PPF)

Boehringer Ingelheim Reports Topline Data from P-III (FIBRONEER-ILD) Study of Nerandomilast for Progressive Pulmonary Fibrosis (PP...

  • February 11, 2025
Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

Boehringer Ingelheim Licenses Synaffix’s Technology to Boost its ADC Portfolio in Oncology

  • January 10, 2025
Boehringer Ingelheim Introduces Vetmedin Solution (Pimobendan Oral Solution), for Congestive Heart Failure in Dogs

Boehringer Ingelheim Introduces Vetmedin Solution (Pimobendan Oral Solution), for Congestive Heart Failure in Dogs

  • November 28, 2024
Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment

Boehringer Ingelheim Join Forces with Circle Pharma to Develop a Novel Precision Cancer Treatment

  • October 10, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.